Contrasting Enzo Biochem (NYSE:ENZ) and Fortrea (NASDAQ:FTRE)

Enzo Biochem (NYSE:ENZ – Get Free Report) and Fortrea (NASDAQ:FTRE – Get Free Report) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, earnings, institutional ownership, analyst recommendations, risk and profitability.

Profitability

This table compares Enzo Biochem and Fortrea’s net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent recommendations for Enzo Biochem and Fortrea, as provided by MarketBeat.com.

Fortrea has a consensus price target of $37.29, indicating a potential downside of 4.52%. Given Fortrea’s higher possible upside, analysts plainly believe Fortrea is more favorable than Enzo Biochem.

Insider and Institutional Ownership

36.9% of Enzo Biochem shares are owned by institutional investors. 15.5% of Enzo Biochem shares are owned by insiders. Comparatively, 0.1% of Fortrea shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Enzo Biochem and Fortrea’s top-line revenue, earnings per share and valuation.

Enzo Biochem has higher earnings, but lower revenue than Fortrea.

About Enzo Biochem

(Get Free Report)

Enzo Biochem, Inc. develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. It also provides AMPIVIEW in situ hybridization probes for enhanced detection of low expressed targets useful in the growing spatial biology space; reagents and assays for cell and gene therapy research and development; POLYVIEW PLUS Enhanced Immunohistochemistry platform, offers solutions within the area of anatomical pathology through optimized assays; Enhanced Immunoassays, pushing sensitivity to expand immunoassay applications for basic research, bioprocess, and diagnostics; AMPIPROBE, a nucleic acid amplification platform; and Axxora.com, a proven distribution platform for original manufacturers of innovative research reagents. The company's proprietary products and technologies in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry, and small molecule chemistry. It markets its products and services through its direct sales force and a network of distributors. The company was incorporated in 1976 and is headquartered in Farmingdale, New York.

About Fortrea

(Get Free Report)

Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. The company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services, as well as consulting services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.